Novartis AG Common Stock (NY:NVS)

Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core...

What Novartis (NVS) Said on Its Q3 Earnings Call ↗

October 27, 2026

Priority brands offset generic erosion as margin expands and pipeline advances.

Topics ETFs Earnings

Novartis (NVS) Q3 2026 Earnings Call Transcript ↗

October 27, 2026

Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker fell short.

Topics Earnings

Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile ↗

September 26, 2026

Via Chartmill

Novartis Hikes Income Forecast, But There Were Caveats Within Its Report ↗

October 27, 2026

Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates and MRI lesion...

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity ↗

October 23, 2026

If Economists Are Correct About the Future of AI, Here Are 2 Global ETFs to Buy -- and 2 to Avoid ↗

Topics ETFs

October 22, 2026

A recent survey shows reasons to be bullish on international stocks. But some global ETFs look more bullish than others.

Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains.

Topics Artificial Intelligence ETFs Economy

Where You Live Shouldn't Limit Your Cancer Care

October 20, 2026

(BPT) - Key takeaways:

Via Brandpoint

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? ↗

October 01, 2026

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗

September 17, 2026

Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022 ↗

September 16, 2026

The pharmaceutical giant's track record in past bear markets is fairly impressive.

Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.

Topics Economy Intellectual Property Stocks

Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares ↗

September 16, 2026

VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗

September 15, 2026

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗

Topics ETFs

September 14, 2026

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.

Amgen Drops 10% on a Trial It Didn't Even Run ↗

September 11, 2026

Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks ↗

September 11, 2026

Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks.

Via Benzinga

Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons ↗

September 08, 2026

Crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, today, Sept. 8, 2026.

Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.

Topics Artificial Intelligence Stocks World Trade

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower ↗

September 08, 2026

Via Benzinga

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling ↗

September 08, 2026

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.

Via Benzinga

How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma ↗

September 08, 2026

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday.

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session ↗

September 08, 2026

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.

Via Benzinga

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners ↗

September 08, 2026

Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.

Via Benzinga

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday ↗

September 08, 2026

Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.

Via Benzinga

Novartis, Ionis Tumble On Surprise Flop For Heart Drug ↗

September 04, 2026

Novartis' Ionis-partnered Lp(a) blocker failed in testing. Both stocks fell.

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.

A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths ↗

September 04, 2026

Via Benzinga

Topics Death

The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win ↗

September 01, 2026

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.

Via Benzinga

Tuesday's session: gap up and gap down stocks ↗

September 01, 2026

Via Chartmill

Why Novartis Just Surged 6%, Eyeing A Breakout ↗

September 01, 2026

Novartis stock surged early Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies.

Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.

VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? ↗

August 23, 2026